MedPath

Efficacy and Safety of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders.

Phase 2
Completed
Conditions
Antibiotic-associated Loose/Watery Stools
Registration Number
NCT01940913
Lead Sponsor
Probi AB
Brief Summary

To assess the tolerability and effect of a probiotic product, when co-administered with antibiotics, on the incidence and duration of loose/watery stools following the antibiotic treatment in children.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Reduction of the incidence of loose/watery stools following antibiotic treatment in children.19-24 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Multicenter study at 13 health care centers in Warsaw

🇵🇱

Warsaw, Poland

Multicenter study at 13 health care centers in Warsaw
🇵🇱Warsaw, Poland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.